article thumbnail

AI-Designed Enzymes

Codon

One study from 2008 (also from the Baker lab) reported de novo enzyme catalysts for Kemp elimination — a reaction that opens up a benzisoxazole ring — by running molecular dynamics simulations to sieve through possible designs.

article thumbnail

Asahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention

The Pharma Data

ART-123: A Novel Therapeutic Candidate Originally approved in Japan in 2008 for disseminated intravascular coagulation, ART-123 functions by mimicking the activity of natural thrombomodulin, an endothelial cell membrane protein that modulates blood coagulation.

Trials 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

Stephan has been with Domain since its inception in 2008 and his roles have evolved over time, including previous positions as Head of Research, Director of Research & Development and Vice-President of Research & Development.

Disease 59
article thumbnail

Outsmarting immune suppression through GPCR innovation

Drug Target Review

Stephan has been with Domain since its inception in 2008 and his roles have evolved over time, including previous positions as Head of Research, Director of Research & Development and Vice-President of Research & Development.

article thumbnail

Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD

Alta Sciences

Advancing Human Abuse Potential Studies at Altasciences At Altasciences, I have been able to focus on abuse potential evaluation, and our team has conducted over 60 HAP, abuse-deterrent formulation (ADF), and substance abuse studies since 2008. I have also supported the 8-factor analyses of many new drugs submitted for NDA approvals.

article thumbnail

Gepirone

New Drug Approvals

Jump up to: a b Halbreich U, Montgomery SA (1 November 2008). Psychological Medicine. 44 (11): 2255–2269. doi : 10.1017/S0033291713002857. PMID 24262766. S2CID 20830020. Archived from the original (PDF) on 18 February 2019. Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders. American Psychiatric Pub. ISBN 978-1-58562-821-6.

FDA 62
article thumbnail

Landiolol

New Drug Approvals

. ^ Jump up to: a b c d [link] ^ “List of nationally authorised medicinal products Active substance: landiolol” (PDF). Procedure no.: PSUSA/00010570/201802. Retrieved 12 October 2024. Ikeshita K, Nishikawa K, Toriyama S, Yamashita T, Tani Y, Yamada T, et al. 22 (4): 3616. doi : 10.1007/s00540-008-0640-4.

FDA 62